1/24/2019: X-Rx Announces FDA Acceptance of IND Application for X-165
X-Rx, Inc., a privately held biotechnology company focused on applying its innovative drug development capabilities to the generation of novel small molecule therapeutics, today announced the US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug Application (IND) for X-165 being developed for the treatment of Idiopathic Pulmonary Fibrosis.
10/02/2018: X-Rx Announces Completion of IND-enabling Studies with X-165 for the Treatment of Idiopathic Pulmonary Fibrosis and other Fibrotic Indications
X-Rx, Inc., a privately held biotechnology company focused on applying its innovative drug development capabilities to the generation of novel small molecule therapeutics, today announced that it has completed IND-enabling studies with X-165, a potent orally available inhibitor of autotaxin, for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic indications.
10/26/2016: X-Rx and Mercachem Provide Update on Two Discovery-Stage Oncology Programs
X-Rx, Inc, a biotechnology company focused on the creation of small molecule drug candidates, and Mercachem BV, a leading chemistry CRO with expertise in medicinal and process chemistry, today reported progress with two discovery-stage oncology programs from the portfolio of X-Rx. The programs target Mcl1, an anti-apoptotic target that is over-expressed in many liquid and solid tumor types, and TAK1, a member of the mitogen-activated protein kinase family.
11/11/2015: X-Rx Announces Autotaxin Inhibitor Collaboration with Gilead Sciences
X-Rx, Inc. announced today that it has entered into an exclusive agreement with Gilead Sciences, Inc. to develop X-Rx’s proprietary small molecule autotaxin (ATX) inhibitors. ATX plays a key role in maintaining tissue homeostasis and is upregulated in many diseases, including idiopathic pulmonary fibrosis (IPF). Inhibition of ATX leads to a reduction in lysophosphatidic acid production, which blocks signaling cascades that ultimately drive the development of fibrosis.